{
    "id": "c1cc0357-ac81-40b6-a401-dfd941495be5",
    "indications": {
        "text": "sildenafil indicated treatment pulmonary arterial hypertension ( group ) adults improve exercise ability delay worsening . delay worsening demonstrated sildenafil added background epoprostenol therapy [ ( 14 ) ] . establishing effectiveness short-term ( 12 16 weeks ) , included predominately patients new york heart association ( nyha ) functional class ii\u2013iii symptoms idiopathic etiology ( 71 % ) associated connective tissue disease ( ctd ) ( 25 % ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "connective tissue disease (DOID:65)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_65"
            },
            {
                "text": "tissue disease (DOID:872)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_872"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "1. tablets oral suspension : 5 mg 20 mg three times day , 4\u20136 hours apart ; full prescribing information reconstitution instructions powder oral suspension ( 2.1 , 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "sildenafil contraindicated patients : \u2022concomitant organic nitrates form , either regularly intermittently , greater risk hypotension [ ( 5.2 ) ] . \u2022concomitant riociguat , guanylate cyclase stimulator . pde-5 inhibitors , including sildenafil , may potentiate hypotensive effects riociguat . \u2022known hypersensitivity sildenafil component tablet oral suspension . hypersensitivity , including anaphylactic reaction , anaphylactic shock anaphylactoid reaction , reported association sildenafil .",
    "ingredients": [
        {
            "name": "SILDENAFIL CITRATE",
            "code": "BW9B0ZE037",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_58987"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        }
    ],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "Sildenafil",
    "effectiveTime": "20201216",
    "indications_original": "Sildenafil is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [see Clinical Studies (14)].\n                  Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II\u2013III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).",
    "contraindications_original": "1. Tablets and oral suspension: 5 mg or 20 mg three times a day, 4\u20136 hours apart; see full prescribing information for reconstitution instructions for the Powder for Oral Suspension ( 2.1 , 2.2 )",
    "adverseReactions_original": "Sildenafil is contraindicated in patients with:\n                  \n                     \n                        \u2022Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.2)].\n                     \n                        \u2022Concomitant use of riociguat, a guanylate cyclase stimulator. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.\n                     \n                        \u2022Known hypersensitivity to sildenafil or any component of the tablet or oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.",
    "drug": [
        {
            "name": "Sildenafil",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9139"
        }
    ]
}